Controversies in Systemic Lupus Erythematosus 2021 Changing the Paradigm in the Management of Lupus Nephritis

Porta S.V.; Enfrein A.; Houssiau F.; García M.; Furie R.; Rovin B.H.; Alarcón G.S.; Pons-Estel B.A.; Pons-Estel G.J. · Journal of Clinical Rheumatology (2022) · DOI: 10.1097/rhu.0000000000001859

Resumen

Lupus nephritis (LN) affects about a third of patients with systemic lupus erythematosus. Although the use of conventional therapy has significantly improved the prognosis of LN, the response to treatment remains suboptimal, with high rates of relapse and the occurrence of endstage kidney disease. The implementation of new diagnostic and treatment strategies aimed at improving these outcomes represents a necessary paradigm shift in the management of LN. Herein, we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the virtual congress of the Pan American League of Associations for Rheumatology (PANLAR) and which was organized by the PANLAR Lupus Study Group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on August 15, 2021.

Instituciones: Universidad Peruana Cayetano Heredia